Hidden in the heart of Mt. Gilead, Ohio sits a pink-hued bakery that’s turning carbohydrates into religious experiences and ...

In the heart of small-town Ohio exists a pink-hued bakery where cinnamon rolls aren’t just breakfast – they’re life-altering ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Gilead’s Sandra Patterson has “decided to leave the company” after two years in the SVP corporate controller and chief ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term ...

It has been about a month since the last earnings report for Gilead Sciences (GILD). Shares have added about 10.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

U.S. equity markets navigated a turbulent month, marked by a noticeable shift in investor risk appetite that gained momentum ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target hoisted by equities researchers at Morgan Stanley from $123.00 to $130.00 in a research note issued to investors on ...